Phytonutrients as a Defensive Barrier Against G Ectodomain Fusion in Chandipura Virus Infection.

IF 2.4 4区 生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY
Jyoti Kumari Yadav, Mohammadfesal Ghanchi, Nandan Dixit, Gaurang Sindhav, Saumya Patel, Rakesh Rawal
{"title":"Phytonutrients as a Defensive Barrier Against G Ectodomain Fusion in Chandipura Virus Infection.","authors":"Jyoti Kumari Yadav, Mohammadfesal Ghanchi, Nandan Dixit, Gaurang Sindhav, Saumya Patel, Rakesh Rawal","doi":"10.1007/s12033-025-01384-x","DOIUrl":null,"url":null,"abstract":"<p><p>Viruses, microscopic menace that transcends time leaving its mark on every era have been silent predators since the dawn of civilization, evolving with us and shaping our history. Chandipura virus (CHPV), a potent member of the Rhabdoviridae family poses a significant threat in India with rapid neuroinvasive potential leading to fatal encephalitis, particularly in children. Given the scarcity of research, our study consolidates critical information regarding its lifecycle, fusion process, and reviewed the LRP1 and GRP78 as CHPV target receptors. With no FDA-approved drugs currently available for CHPV prevention, our research focuses on identifying potential molecules that can disrupt the virus at its most critical juncture, the fusion stage. The results derived from compounds screening indicated Silibinin, 3-(2,3-Dihydroxy-3-Methylbutyl)-6-Hydroxy-2-[(1E,5E)-3,4,10-Trihydroxyundeca-1,5-Dienyl] Benzaldehyde, Budmunchiamine L5, and L4 as a leading molecule may efficaciously inhibit G ectodomain fusion. By analyzing pharmacokinetic properties through radar graph, outcomes support the nomination of four compounds as potential inhibitory molecules and ensure they possess the optimal balance of drug-like characteristics. Working with the CHPV presents significant challenges, making the in silico parameters crucial in guiding future research. Our study sought to pioneer the discovery of therapeutic molecules against the CHPV, providing a foundational framework for developing effective antiviral strategies.</p>","PeriodicalId":18865,"journal":{"name":"Molecular Biotechnology","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Biotechnology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12033-025-01384-x","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Viruses, microscopic menace that transcends time leaving its mark on every era have been silent predators since the dawn of civilization, evolving with us and shaping our history. Chandipura virus (CHPV), a potent member of the Rhabdoviridae family poses a significant threat in India with rapid neuroinvasive potential leading to fatal encephalitis, particularly in children. Given the scarcity of research, our study consolidates critical information regarding its lifecycle, fusion process, and reviewed the LRP1 and GRP78 as CHPV target receptors. With no FDA-approved drugs currently available for CHPV prevention, our research focuses on identifying potential molecules that can disrupt the virus at its most critical juncture, the fusion stage. The results derived from compounds screening indicated Silibinin, 3-(2,3-Dihydroxy-3-Methylbutyl)-6-Hydroxy-2-[(1E,5E)-3,4,10-Trihydroxyundeca-1,5-Dienyl] Benzaldehyde, Budmunchiamine L5, and L4 as a leading molecule may efficaciously inhibit G ectodomain fusion. By analyzing pharmacokinetic properties through radar graph, outcomes support the nomination of four compounds as potential inhibitory molecules and ensure they possess the optimal balance of drug-like characteristics. Working with the CHPV presents significant challenges, making the in silico parameters crucial in guiding future research. Our study sought to pioneer the discovery of therapeutic molecules against the CHPV, providing a foundational framework for developing effective antiviral strategies.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Molecular Biotechnology
Molecular Biotechnology 医学-生化与分子生物学
CiteScore
4.10
自引率
3.80%
发文量
165
审稿时长
6 months
期刊介绍: Molecular Biotechnology publishes original research papers on the application of molecular biology to both basic and applied research in the field of biotechnology. Particular areas of interest include the following: stability and expression of cloned gene products, cell transformation, gene cloning systems and the production of recombinant proteins, protein purification and analysis, transgenic species, developmental biology, mutation analysis, the applications of DNA fingerprinting, RNA interference, and PCR technology, microarray technology, proteomics, mass spectrometry, bioinformatics, plant molecular biology, microbial genetics, gene probes and the diagnosis of disease, pharmaceutical and health care products, therapeutic agents, vaccines, gene targeting, gene therapy, stem cell technology and tissue engineering, antisense technology, protein engineering and enzyme technology, monoclonal antibodies, glycobiology and glycomics, and agricultural biotechnology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信